Standardised Report for Molecular Imaging Studies

Clinical details

Indication:

Other:

Primary location: *Other:*

Pathology:

Inherited/clinical syndrome: *Other:*

Other relevant clinical information: *Other:*

Procedure

Radiopharmaceutical: *Other:*

Administered activity: MBq

Uptake time: min h^{-1}

Scan type: *Region:*

Image range: *Other:*

Interventions:

Other relevant procedural information:

Abbreviations: DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; MIBG,metaiodobenzylguanidine.

Comparative imaging

CT: Date:

MRI: Date:

^{111}In-pentetreotide: Date:

SSTR (SSR) PET/CT: Date:

FDG: Date:

Other: Date:

Findings

Primary location: *Other:*

Primary Avidity: *Reference (spleen, liver):*

Primary size (cm):

Primary characteristics:

Nodes:

Nodal characteristics *(enter information on size and location)*:

Metastases:

Metastases locations *(Please select as many as many as applicable:*

Other:

Other:

Other:

Other:

Other:

Metastases characteristics (e.g. size, number or heterogeneity/necrosis):

Metastases characteristics (overall lesion intensity, e.g. Krenning score):

Reference Lesions

Region	Lesion descriptor (location)	Visual Avidity (e.g. Krenning Score)	Semiquanti-tative avidity (e.g. SUV$_{max}$)	Tumor to spleen SUV$_{max}$ ratio	Somatostatin Receptor-FDG relationship	Size (uni- or bi-dimensional)
Head and neck						
Thorax						
Abdomen						
Pelvis						
Appendicular						

Abbreviation: SUVmax maximum standard unit value.